a v Integrins have been shown to play an important role in epithelial-derived cell migration, cell growth and tumor invasion/metastasis, however their role on cells of hematopoietic origin is less clear. Epstein-Barr virus (EBV), a human herpesvirus associated with several lymphoproliferative disorders in man, induces expression of a v integrins on transformed B lymphocytes. In the studies reported here, we show that EBV infection increases a v , b 3 and b 5 integrin subunit mRNAs as well as upregulates the expression of the a v b 3 integrin protein on human B cells. Among the nine dierent EBV proteins expressed in latently infected B cells (nuclear and plasma membrane-associated), only LMP1, LMP2A and EBNA2 were shown to selectively transactivate the a v integrin promoter. Treatment of EBV-transformed B cells with a v antisense oligonucleotides speci®cally reduced cell surface expression of a v integrins, inhibited cell growth in low serum, reduced cell invasion in matrigels and decreased expression of metalloprotease, MMP9. These studies indicate that a v integrins play a signi®cant role in EBV-induced B-lymphocyte proliferation and invasion. Strategies to interfere with a v integrin expression and/or function may therefore be of potential value in the treatment of EBV-associated lymphoproliferative disorders.
Introduction
The oncogenic potential of Epstein-Barr virus (EBV), a member of the herpesvirus family, is mirrored in vitro where establishment of a latent infection in human B lymphocytes leads to the outgrowth of immortalized lymphoblastoid cell lines (LCLs) (Henle et al., 1967; Pope, 1967) . EBV gene expression in LCLs is restricted to six nuclear antigens (EBNA1, 2, 3A, 3B, 3C, and LP), three integral membrane proteins (LMP1, 2A, and 2B) and two non-polyadenylated EBV-encoded RNAs (EBER1 and 2), resembling the gene expression pattern in tumors from immunocompromized patients with EBV lymphoproliferative disease (Rickinson and Kie, 1996; Kie, 1996) . Furthermore, the dissemination of LCL in SCID mice is similar to the diuse distribution of EBV-associated lymphomas in immunocompromised patients (Rickinson and Kie, 1996) . Since LCLs share characteristics with in vivo transformed B lymphocytes, they have been used as a model for investigating EBVinduced B-cell tumorigenicity (Epstein and Achong, 1973) . LCL also have increased expression of several cell adhesion molecules including a v integrins (Huang et al., 1997; Stupack et al., 1992) .
Integrins are heterodimeric molecules composed of a noncovalently associated a and b subunit (Hynes, 1992) . a v Integrins include a v b 1 , a v b 3 , a v b 5 , a v b 6 , and a v b 8 and exclusively recognize ligands via an RGD amino acid sequence (Hynes, 1992) . The ligands for a v integrins include vitronectin, ®bronectin, ®brinogen, von Willebrand factor, and osteopontin (Pytela et al., 1985; Zhang et al., 1993; Denhardt and Guo, 1993; Charo et al., 1990; Busk et al., 1992; . Several lines of evidence have demonstrated a crucial role of a v integrin in tumor development of various cancers. First, a v integrins are expressed on migratory cells such as metastatic melanomas and breast cancer cells and integrin expression correlates well with metastasis (Nip et al., 1997; Filardo et al., 1995; Albelda et al., 1990) . Second, a v b 3 is directly associated with matrix metalloproteinase 2 (MMP2) on melanoma cells (Brooks et al., 1996) . The colocalization of a v b 3 integrins and MMP2 is believed to provide tumor cells with the coordinated matrix degradation and cellular motility, thus facilitating cellular invasion (Varner and Cheresh, 1997) . Third, certain breast carcinoma can spontaneously metastasize through the functional cooperation of a v b 5 integrin and cytokines such as IGF (Brooks et al., 1997) .
While previous studies have demonstrated increased expression of a v integrins on LCLs (Huang et al., 1997) , the identity of EBV-encoded gene(s) having a direct role in regulating a v integrin expression has not been established. Moreover, it has not been determined whether a v integrin expression plays a signi®cant role in EBV-induced B-cell growth or tumorigenicity. In this report, we identify several EBV gene products that transcriptionally regulate expression of the a v subunit in B lymphocytes and provide evidence that the expression of a v integrin regulates LCL cell growth and the invasive phenotype.
Results

EBV infection induces a v integrin expression on human B lymphocytes
Our previous studies have shown that primary human B lymphocytes express very little if any a v integrins. In contrast, both a v b 3 and a v b 5 integrins are readily detected on EBV-transformed B cells (LCLs) (Huang et al., 1997) . Therefore, we hypothesized that certain EBV-encoded genes were responsible for inducing a v integrin expression on these cells. To investigate this possibility, we ®rst examined a v integrin expression on an EBV-negative B lymphoblastoid cell line, JR2B10 (Stupack et al., 1991) at varying times after EBV infection. EBV was not present in JR2B10 cells as determined by PCR detection of EBNA 1 mRNA ( Figure 1A) ; however, the presence of EBV could be readily detected by 3 days postinfection.
We next examined a v b 3 integrin on JR2B10 cells following EBV infection. No a v b 3 integrin was detected on uninfected JR2B10 cells by immunoprecipitation ( Figure 1B) ; while, in contrast, a v b 3 integrin was detected on JR2B10 cells 5 days post-EBV infection ( Figure 1B ). To determine whether EBV-induced integrin expression was due to regulation of mRNA levels, we next performed RT ± PCR on EBV-JR2B10 cell extracts. No a v , b 3 , or b 5 mRNA was detected in uninfected JR2B10 cells ( Figure 1C ). In contrast, mRNAs encoding a v and b 3 integrin subunits were detected as early as 2 days post-EBV infection. b 5 mRNA expression was detected on day 5 post-EBV infection ( Figure 1C ). Furthermore, we found that a v integrins expressed on JR2 and EBV-infected JR2B10 cells supported cell adhesion and migration on extracellular matrix vitronectin, a ligand for a v integrins (data not shown). These results demonstrated that EBV infection results in the upregulation of both a (a v ) and b (b 3 and b 5 ) integrin subunits in human B lymphocytes. Moreover, the increased expression of integrin subunits is due at least in part to transcriptional regulation.
EBV latent gene proteins LMP1, LMP2A, and EBNA2 transactivate the a v subunit promoter Since EBV infection upregulates a v integrin expression we next sought to identify the EBV genes responsible. For these studies, we used a reporter gene plasmid containing the a v integrin promoter driving the luciferase reporter gene (pla v P). A 15.5 Kb DNA fragment containing the 5' end of the a v integrin subunit gene was previously isolated from a human leukocyte genomic library (Donahue et al., 1994) . Functional analysis showed that the 690 bp sequence upstream of the ATG translation initiation site contained promoter activity (Figure 2A ). In addition, the transcription initiation site was mapped to 169 bp upstream of the ATG site (Donahue et al., 1994) . JR2B10 cells were transfected with pla v P; and 48 h later, the cells were analysed for a v integrin subunit promoter activity. JR2B10 cells showed no promoter activity above the background in untransfected or pGL2 basic-transfected JR2B10 cells ( Figure 2B ). In contrast, a substantial increase in promoter activity was detected in EBV-infected JR2B10 as well as the EBV positive parental JR2 cells ( Figure 2B ). These results suggested that EBV infection induces a v integrin expression by transactivating the a v integrin promoter in B lymphocytes.
There are nine EBV latent proteins constitutively expressed in LCLs (Rickinson and Kie, 1996) . To test the possibility that one or more of these EBV latent proteins is responsible for activating the a v integrin subunit promoter, pla v P was co-transfected into JR2B10 cells with mammalian expression vectors encoding either EBNA1, 2, 3A, 3B, 3C, LP and LMP1, 2A, or 2B genes and cell lysates were assayed 48 h later for a v integrin promoter activity. Transfection of cells with EBNA1, 3A, 3B, 3C, LP and LMP2B vectors had little or no eect on luciferase activity, despite the fact that these proteins were capable of being expressed in JR2B10 cells as ascertained by RT ± PCR and/or Western blot (data not shown). In contrast, expression of LMP1 and 2A signi®cantly enhanced a v integrin promoter activity (24-and 16-fold above the pSI/bgal-transfected cells, respectively), while ENBA2 induced only a small increase in promoter activity (sixfold above the control) ( Figure 2C ). These results suggest that increased a v integrin expression in EBV-infected B cells is likely to be induced by the EBV latent proteins LMP1, LMP2A and to a lesser extent to EBNA2. We next investigated the ability of EBNA2, LMP1 and LMP2A to induce endogenous a v integrin mRNA expression. JR2B10 cells were transfected with mammalian expression vectors encoding EBNA1, 2 and LMP1, 2A individually or in dierent combinations. RT ± PCR was then used to detect a v integrin mRNA expression. No a v mRNA was detected in either mock or EBNA1-transfected cells ( Figure 2D ). EBNA2 expression in JR2B10 cells also did not induce detectable a v mRNA, even though it weakly transactivated the a v integrin promoter ( Figure 2C,D) . In contrast, LMP1 or LMP2A alone induced a v mRNA expression, while the combined expression of LMP1 and 2A induced 5 ± 8-fold greater a v mRNA expression in these cells ( Figure 2D ). These results suggest that LMP1 and LMP2A may work synergistically to transactivate a v integrin expression in EBV-transformed B cells.
a v Integrin expression is essential for LCL growth in reduced serum
A well-known property of EBV transformed cells is their ability to proliferate in tissue culture under low serum conditions. We thus compared the growth properties of a v (7) vector for 48 h, total RNA was then isolated from these cells and subjected to RT ± PCR using speci®c primers for a v integrin subunit. RT ± PCR primers for GAPDH were also used as an internal control Oncogene a v Integrins regulate B cell growth and invasion S Huang et al also able to proliferate in low serum conditions, similar to that of the parental JR2 cells (data not shown). These results suggested that EBV infection conferred on B-cells the ability to grow in reduced serum.
In order to determine whether the expression of a v integrins played a direct role in JR2 cell growth in reduced serum, we treated cells with three a v integrin subunit-speci®c antisense oligonucleotides ( Figure 4A ). As determined by an ELISA, two dierent antisense oligonucleotides, one directed to the AUG site (AS2) and the other to a sequence upstream of AUG site (AS1), greatly reduced the level of a v integrins in JR2 cells. Transfection of cells with antisense oligonucleotide reduced the levels of a v integrins approximately 90% ( Figure 4B ). In contrast, transfection of cells with these antisense oligonucleotides failed to alter the expression of b 1 integrins ( Figure 4B ). In addition, an antisense oligonucleotide (AS3), directed against a sequence downstream of the AUG translation initiation site in the a v subunit, failed to alter a v integrin levels on JR2 cells ( Figure 4B ). Furthermore, immunoblot analysis con®rmed that the AS2 or AS1 antisense oligonucleotides signi®cantly reduced a v protein but did not signi®cantly inhibit the expression of an intracellular protein, b-actin ( Figure 4C ). Together, these results demonstrate the speci®city and ecacy of these antisense oligonucleotides.
We next investigated the eect of a v -speci®c antisense oligonucleotides on JR2 growth. AS2 or AS1 signi®cantly inhibited LCL growth in medium Figure 4B ) also did not aect JR2 cell growth in either 0.1% or 5% FCS-containing medium ( Figure 5 ). Similarly, AS2 and AS1, but not AS3, signi®cantly inhibited EBV-infected JR2B10 cell growth in medium containing 0.1% FCS but not 5% FCS (data not shown). We also performed identical studies on RPMI8866 and SKW6.4 cell lines, which are B-lymphoblastoid cell lines previously established from patients with EBV-associated lymphoproliferative disorders. Similar to JR2 cells, the AS2 antisense signi®cantly reduced cell growth of RPMI8866 and SKW6.4 in 0.1% FCS, but showed no eect on the cell growth of these cells in 5% FCS (data not shown).
These results indicate that the expression of a v integrins plays a role in one of the tumorigenic properties of EBV-transformed B cells, namely the ability to proliferate in low serum.
a v Integrin promotes B-lymphoblastoid cell tumor invasion
Expression of cell adhesion molecules has been closely associated with the invasive properties of tumor cells (Varner and Cheresh, 1997) , and thus it was of interest to determine whether EBV-induced a v integrin expression contributes to B-cell invasion. We found that JR2B10 cells did not invade matrigel ( Figure 6A , panel a), a cell matrix containing collagen and other matrix proteins, but instead these cells remained spread on the surface of the matrix. In contrast, JR2 and EBVinfected JR2B10 cells showed signi®cant invasion into the deepest layer of the matrigel ( Figure 6A ,B). Since invasion of tumor cells is frequently associated with the expression of cell-surface and/or secreted metalloproteases, we next performed gelatin zymograms to examine whether JR2B10, EBV-infected JR2B10 and JR2 cells exhibited this property. Collagenase activities, consistent with proMMP9 (92 kDa) and MMP9 (88 kDa), were signi®cantly elevated on EBV-infected JR2B10 or JR2 cells compared to JR2B10 cells ( Figure 6C , compare lane 1 and lanes 2,3). These results are consistent with our observation that EBV-positive B cells (EBV-infected JR2B10 and Figure 6A,B) .
We next investigated whether the expression of a v integrins plays a role in the invasive property of EBV transformed B cells. JR2 cells were treated with antisense nucleotides AS2 or AS3 and their ability to invade matrigels and display collagenase activities was examined 36 h later. AS2, but not AS3, signi®cantly inhibited JR2 invasion on matrigel ( Figure 6A,B) . Furthermore, AS2 also greatly decreased collagenase activities of JR2 cells ( Figure 6C ). We also studied the eect of a v -speci®c antisense oligonucleotides on the invasive properties of RPMI8866 and SKW6.4 cells. Similar to JR2 cells, treatment of these cells with AS2 led to 82 and 74% of reduction in the number of invading cells (data not shown). These results suggest that a v integrins not only play a role in cell proliferation but also in extracellular matrix invasion.
Discussion
Our previous studies have demonstrated that a v integrins are expressed on EBV-immortalized human B lymphocytes (LCLs), but not on primary human B lymphocytes (Huang et al., 1997) . However, it was not clear whether the expression of a v integrins is directly associated with EBV infection in human B lymphocytes. The establishment of B-lymphoblastoid cell lines, which either contain or lack EBV genomes, provided an opportunity to address this question. For example, JR2B10 cells, a subclone derived from JR2 LCL line had lost episomal EBV DNA after immortalization (Stupack et al., 1991) and these cells also lack a v integrins ( Figure 1B,C) . Re-infection of JR2B10 cells with EBV also restored expression of a v integrins (Figure 1 ). These ®ndings suggested a link between EBV gene and integrin a v expression. To test this possibility, we introduced a potent EBNA1 speci®c ribozyme into EBV+JR2 cells. This ribozyme was previously demonstrated to reduce EBV genomes in LCLs (Huang et al., 1997) , and it also decreased a v b 3 integrin expression in LCLs (Huang and Nemerow, unpublished data) . Taken together, these ®ndings strongly suggested that the expression of a v integrins is closely associated with the presence of EBV genes in human B lymphocytes.
While a v integrins are normally constitutively expressed in most epithelial-derived cells, we considered the possibility that this might not be the case in hematopoietic cells and that EBV might play a role in enhancing transcription of a v integrin subunits in B lymphocytes. We demonstrated that the a v integrin subunit promoter (Figure 2A ) was constitutively active in EBV-positive B cells (JR2 and EBV-infected JR2B10) but not in EBV-negative JR2B10 cells ( Figure  2B ). Moreover, we showed that EBV latent proteins including LMP1 and 2A were capable of transactivating the a v integrin promoter and inducing a v integrin mRNA expression in B cells (Figure 2C,D) . These results suggest that the expression of a v integrins may be induced through the transcriptional activation of a v integrin subunit by EBV latent proteins. Currently, we do not know whether EBV latent genes also transcriptionally activate b 3 or b 5 integrin subunits. a v Integrins have been implicated in tumor cell growth, angiogenesis, tumor cell invasion and metastasis in melanomas and breast cancer cells (Varner and Cheresh, 1997) . In the present study, we sought to determine the role of a v integrins in LCL tumorigenicity by using a v -speci®c antisense oligonucleotides to downregulate the expression of a v integrins on LCLs. Two oligonucleotides, one of which targets the region upstream of the AUG translation initiation site and the other, the AUG site itself, were capable of reducing a v integrin expression by approximately 90% ( Figure  4B,C) ; whereas expression of b 1 integrin was not aected. When JR2 or EBV-infected JR2B10 cells were treated with these two antisense oligonucleotides, cell growth was signi®cantly inhibited in medium containing 0.1% fetal calf serum, a property of tumorigenic cells. However, these oligonucleotides exhibited no eect on cell growth in 5% serum ( Figure 5 ). These results strongly suggest that a v integrins may play an important role in LCL growth in reduced serum. Several previous studies have shown that ligation of a v b 3 promotes cell survival in various cell types (Montgomery et al., 1994; Scatena et al., 1998) , and that blocking a v b 3 integrin with function-antagonists triggers apoptosis of endothelial cells (Brooks et al., 1996) . Therefore, expression of a v integrins may facilitate LCL cell growth by blocking apoptosis of these cells in reduced serum. Since several antiapoptosis molecules including bcl-2 and A20 are overexpressed in LCLs (Eliopoulos and Rickinson, 1998) , a v integrins may work in concert with these proteins to promote B-cell survival and cell growth.
In the present study, we demonstrated that LCLs (JR2 and EBV-infected JR2B10) possessed the capability to invade cell matrix proteins while EBVnegative JR2B10 cells did not ( Figure 6A,B) . Zymography studies showed signi®cantly greater collagenase activities in EBV-positive cells (JR2 and EBV-infected JR2B10) than JR2B10 cells ( Figure 6C ). Recent studies have reported that LMP1 enhances metalloproteinase 9 (MMP9) expression on epithelial cells (Yoshizaki et al., 1998) . Since this protease has the capacity to eciently digest collagen, this ®nding may explain the invasive properties of LCLs. Interestingly, when antisense oligonucleotides were used to reduce the expression of a v integrins, we observed a signi®cant decrease in matrigel invasion and collagenase activities of LCLs ( Figure 6C ). The inhibition of JR2 invasive phenotype was apparently due to the downregulation of a v integrins since the nonfunctional AS3 antisense oligonucleotide did not show any eect (Figure 6 ). Brooks et al (1996) have reported that a v b 3 directly associates with metalloproteinase 2 (MMP2) thus allowing it to be localized, in a proteolytically active form, on the surface of cancer cells to promote tumor invasion. It is possible that MMP9 acts in a similar fashion. Therefore, downregulation of a v integrins may disrupt the association of collagenases with a v integrins, subsequently decreasing collagenase activities and thus the invasive properties of LCLs.
In the present study, we demonstrate that a v integrins play an important role in cell growth and tumor invasion of EBV-infected B lymphocytes (LCLs). Clearly, further studies are needed to de®ne the precise mechanisms involved in a v integrinsinvolved LCL cell growth and invasion. Such knowla v Integrins regulate B cell growth and invasion S Huang et al edge would provide further insights into EBV-associated B-cell malignancies, and may allow the development of therapeutic approaches to block EBVassociated malignancies by preventing a v integrin expression or function.
Materials and methods
Cells, antibodies and reagents
JR2 is a lymphoblastoid cell line (LCL), developed by immortalizing freshly isolated human peripheral blood cells with EBV (Stupack et al., 1992; Wilkins et al., 1983) . JR2B10 is a subclone derived from JR2, which subsequently lost the EBV genome after immortalization (Stupack et al., 1991) . SKW6.4 (ATCC, Rockville, MD, USA) and RPMI8866 (Stupack et al., 1991 (Stupack et al., , 1992 are EBV-positive B-lymphoblastoid cell lines derived from patients with lymphoproliferative disorders. All cells were maintained in RPMI-1640 containing 10% FCS. Monoclonal antibodies LM609 (anti-a v b 3 ), P1F6 (anti-a v b 5 ) and LM142 (anti-a v ) are commercially available from Chemicon (Temecula, CA, USA). Monoclonal antibody 69-6-5 (anti-a v ) was a generous gift from Dr Maxime Lehmann (UniversiteÂ de Aixmarseille, France). Fibronectin was purchased from Upstate Biotechnology Inc. (Lake Placid, NY, USA). Vitronectin was puri®ed as previously described (Yatohgo et al., 1988) . Transwells (8.0 mm pore size) were purchased from Costar (Corning NY, USA). The matrigel invasion chambers (BIOCOAT) were purchased from Becton Dickinson (Bedford, MA, USA). Precast 10% Zymogram gels were purchased from Novex (San Diego, CA, USA).
Antisense oligonucleotides, PCR and RT ± PCR
Antisense oligonucleotides directed against a v integrins were synthesized by Oligos Etc (Wilsonville, OR, USA). These chimeric oligonucleotides have higher speci®city and stability than phosphorothioate oligonucleotides. We designed three antisense oligonucleotides (AS) speci®c for the a v integrin subunit ( Figure 6A ). AS1 was directed the region upstream from AUG translation initiation site, AS2 at the AUG site, and AS3 at the region downstream from AUG site. All sequences were unique to the a v integrin subunit and had no self-complementarity as determined by computer analysis (PCGene software, Intelligenetics, Mountain View, CA, USA). The Tm for these oligonucleotides were 75.9, 64.5, and 78.28C respectively. Transfection of cells with oligonucleotides was performed using Lipofectamine as recommended by the manufacturer (GIBCO BRL, Gaithersburg, MA, USA). EBV infection of JR2B10 cells was analysed by PCR as follows. B95-8 cell supernates containing the transforming strain of EBV was added to JR2B10 cells and then cultured for varying times. Genomic DNA was then isolated from these cells (Easy-DNA kit, Invitrogen, Carlsbad, CA, USA) and 2 mg of DNA was used in PCR reactions (948C, 1 min; 558C, 1 min; 728C, 1 min; 30 cycles) to detect the presence of the EBV genome on 1% TBE-agarose gels. The primers for EBV genome were EBNA1a (5'-GGTAGAGGACGTGAAA-GAGCCAG-3') and EBNA1b (5'-ATCGCATCCTT-CAAAACCTCAGC-3'), corresponding to nucleotide bp 109 012 ± 109 034 and 109 663 ± 109 685 in the B95-8 EBV genome, respectively.
To examine the eect of EBV infection on the expression of a v , b 3 , and b 5 integrin subunit mRNA, JR2B10 cells were infected with EBV for various times. Subsequently, total RNA was isolated from these cells (Trizol reagent, GIBCO-BRL), and then treated with RNase-free DNase I (Promega, Madison, WI, USA) to remove any contaminating DNA.
Total RNA (2 mg/reaction) was used as a template to synthesize cDNA using an oligo (dT) 15 primer and AMV reverse transcriptase (Promega) in a 20 ml reaction volume. The reaction mixture was heated to 958C for 5 min and 5 ml of this reaction was subjected to 30 cycles of PCR (948C, 1 min; 558C, 1 min; 728C, 1 min) using speci®c primers for a v , b 3 , b 5 integrin subunits. RT ± PCR for GAPDH mRNA was performed as an internal control. Reaction products were analysed on 1% TBE-agarose gels.
The primers for a v integrin subunit were (Ava) (5'-GTTGGGAGATTAGACAGAGGA-3') and (Avb) (5'-CAAAACAGCCAGTAGCAACAA-3') oligonucleotide primers corresponding to bp 2787 ± 2807 and 3074 ± 3054 respectively, based on the published sequence (Gene Bank Accession Number: M14648). The primers for b 3 integrin subunit were (B3a) (5'-GGGGACTGCCTGTGTGACTC-3') and (B3b) (5'-CTTTTCGGTCGTGGATGGTG-3') primers corresponding to bp 1729 ± 1748 and 2272 ± 2253 (Gene Bank Accession Number: J02703). The primers for b 5 integrin subunit were (B5a) (5'-GAGGAAGTTCGGAAACAGAGG-3') and (B5b) (5'-GTTCCAGGTATCAGGGCTGTA-3') corresponding to bp 740 ± 760 and 1110 ± 1090 (Gene Bank Accession Number: J05633). The primers for GAPDH mRNA were (Ga) (5'-CTGAGAACGGGAAGCTTGTC-3') and (Gb) (5'-CCTGCTTCACCACCTTCTTG-3').
Immuno-detection of a v integrin expression
To examine the eect of EBV infection on expression of a v b 3 integrin, B95-8 culture supernatant containing the transforming strain of EBV was added into JR2B10 cells for various times. The cells (5610 7 cells/sample) were then washed three times with phosphate-buered saline pH 7.4 (PBS), and surface labeled with Na 125 I (1 mCi/sample, Amersham, Arlington Heights, IL, USA) in 1 ml of PBS for 30 min at 228C using lodobeads (Pierce). The labeled cells were extensively washed to remove free iodide, and then lysed in 0.5 ml of lysis buer (200 mM Tris pH 8.0, 150 mM NaCl, 0.5% NP-40, 0.5% BSA, 5 mM EDTA, 0.5% Tween-20, 10 mg/ml leupeptin, and 10 mg/ml aprotinin) on ice for 1 h. The lysates were ®rst pre-cleared by incubating with 100 ml of Pansorbin (Calbiochem, San Diego, CA, USA) for 1 h, and then incubated with anti-a v b 3 mAb LM609 for 2 h. The precleared immune complexes were then reacted with Protein-G beads (Pharmacia, Alameda, CA, USA) for 1 h at 48C, followed by centrifugation. The beads were then washed twice with 500 mM NaCl, twice with 150 mM NaCl and then boiled in 26SDS sample buer and electrophoresed on a 7% SDS-polyacrylamide gel. The gel was dried and exposed to Xray ®lm (X-OMAT, Kodak) for 2 days.
To measure the ecacy of a v -speci®c antisense oligonucleotides, JR2 cells were plated in polylysine-coated 96-well plates for 20 h. Antisense oligonucleotides ranging in concentration from 0.5 to 15 mM were added into wells with 2 ml of lipofectamine in a total volume of 200 ml for 36 h. Cells were ®xed with 2% paraformaldehyde for 15 min, then blocked with 3% BSA for 1 h at room temperature. Integrin expression was then assayed by addition of the anti-a v mAb (ascites), LM142, at 1 : 100 dilution for 1 h at room temperature. After several washes, HRP-conjugated goat anti-mouse antibody (1 : 1000) (KPL, Gaithersburg, MA, USA) was added to the wells for 1 h. After washing the wells, an HRP substrate solution (KPL) was added to each well and the reactions were quantitated in an ELISA plate reader at 405 nm.
a v Integrin subunit expression was also analysed by immunoblotting using the anti-a v mAb, VNR137 (Chemicon, Temecula, CA, USA). Brie¯y, JR2 cells were lysed in cell lysis buer (50 mM Tris, pH 8.0, 0.02% NaN 3 , 0.1% SDS, 100 mg/ml PMSF, 1 mg/ml Aprotinin, 1% NP40 and 0.5% Na deoxycholate), and after centrifugation, the cell lysates (75 mg per sample) were electrophoresed on a 8% polyOncogene a v Integrins regulate B cell growth and invasion S Huang et al acrylamide gel. The proteins were then transferred onto a PVDF membrane (Immobilon P, Amersham). Nonspeci®c binding sites on the membrane were then blocked by incubation in 5% nonfat dry milk. The blot was then reacted at room temperature for 2 h with a 1 : 1000 dilution of the VNR137. a v Integrin subunit was detected by incubation with a 1 : 5000 of HRP-conjugated rabbit anti-mouse antibody followed by addition of chemiluminescence detection (SuperSignal solution Pierce, Rockford, IL, USA).
Cell surface expression of a v integrin were also determined by¯ow cytometry using anti-a v mAb (LM142) as described previously (Huang et al., 1995) .
Transfection and a v integrin subunit promoter activity assay A 690 bp fragment containing the a v integrin promoter was synthesized by PCR based on the published sequence (Gene Bank Accession Number: U07375) using genomic DNA isolated from JR2 cells as a substrate. The primers were la v Pa (5'-GAAAGATCTAGCTTTCCTCATTTTTAAACA-ACAG-3', underline sequence is BglII site) and la v Pb (5'-ATTCAAGCTTCGCCGAAGTGCGCGCGG-3', underline sequence is HindIII site). The PCR-synthesized a v integrin subunit promoter was digested with BglII/HindIII and subcloned into the promoterless pGL2 basic vector (Promega) which contains a luciferase gene (Figure 2A ). The sequence of the a v integrin subunit promoter was con®rmed by automated DNA sequencer and found to be identical to the published sequence. We designated this a v integrin subunit promoter reporter gene plasmid as pla v P.
To analyse a v integrin subunit promoter activity in JR2 and JR2B10 cells, 20 mg of pla v P with 2 mg of pRSVb (containing the b-galactosidase gene, Promega) and 13 mg of pBSK (used as carrier DNA, Stratagene, San Diego, CA, USA) was electroporated into 10 7 cells (300 V, 960 FD). After 36 h, the cells were lysed and the luciferase activity was determined (Luciferase Assay System, Promega). The bgalactosidase activity was determined using ONPG as previously described (Huang et al., 1996) and used to standardize a v integrin subunit promoter activity. To determine the eect of EBV latent genes on a v integrin subunit promoter activity, JR2B10 cells were electroporated with 20 mg of pla v P, 2 mg of pRSVb and 13 mg of EBV latent gene expression vectors (EBNA1, 2, 3A, 3B, 3C, LP and LMP1, 2A, 2B in plasmid pSI, Promega).
Cell growth and proliferation
Cell growth was assessed by counting cells by light microscopy. Brie¯y, 2610 5 cells were plated into 6-well plates and allowed to grow in medium containing 5% serum or 0.1% serum for various times. The cells were then removed from the wells, and cell growth was determined by counting number of viable cells (determined by trypan blue dye exclusion) in each well.
To examine the eect of antisense oligonucleotides on LCL (JR2, SKW6.4 and RPMI8866) cell growth, cells were transfected with 10 mM antisense oligonucleotides and then cultured for 20 h. Cells were then allowed to grow in medium containing 5% serum or 0.1 serum for 3 days, and the number of cells was quantitated by MTT assay as described previously (Huang and Chakrabarty, 1994) .
Matrigel invasion assay and zymograph
Cell invasion was analysed using BIOCOAT matrigel invasion chambers (Becton-Dickinson) according to the protocol provided by the manufacturer. Brie¯y, 2610 5 cells in 300 ml were added to each chamber and allowed to invade matrigel for 20 h at 378C, 5% CO 2 atmosphere. The noninvading cells on the upper surface of membrane were removed from the chambers, and the invading cells on the lower surface of membrane were stained with Di-Quick stain kit (Becton Dickinson). After two washes with water, the chambers were allowed to air dry. The number of invading cells were then counted using a phase-contrast microscope. To determine the eect of a v -speci®c antisense oligonucleotides on JR2, SKW6.4 and RPMI8866 invasive property, cells were treated with 10 mM of antisense oligonucleotides in the presence of lipofectamine for 20 h. After several washes, cells were added into invasion chambers, and the number of invading cells was determined.
Collagenase activities were determined using precast 10% zymograph gels (Novex, San Diego, CA, USA). Brie¯y, cells were washed with serum-free medium three times, then resuspended in serum-free medium at 10 7 cells/ml, and cultured for 20 h. The cells were spun down, and the media was collected and concentrated using 10K Centricon (2.5 to 0.5 ml). The concentrated conditioned media (15 ml) was mixed with 46SDS sample buer for 10 min at room temperature, and then electrophoresed on 10% polyacrylamide gel containing gelatin. After electrophoresis, the gels were treated with renaturing buer followed by incubation in developing buer for 16 h at 378C as described by the manufacturer. The gels were stained with 1% Coomassie blue for 30 min, and destained by several washes with water.
Accession number
The accession numbers for primer sequences cited in this study are listed again here for quick reference. Ava and Avb, GeneBank Acc. No. M14648; B3a and B3b, Genebank Acc. No. J02703; B5a and B5b, Genebank Acc. No. J05633; IavPa and IavPb, GeneBank Acc. No. U07375.
